Results to be Presented in Late-Breaking Session Results to be Presented in Late-Breaking Session

Read more here:
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular...

Global News Feed Comments Off on Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular… | June 20th, 2022

First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune suppression

Go here to read the rest:
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types...

Global News Feed Comments Off on Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types… | June 20th, 2022

ANAHEIM, CA, June 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Tom Welch, Executive Vice President of BioCorRx Inc., was featured on LiveNOW from FOX. Mr. Welch discussed BioCorRx’s pilot program with 2B3D, a virtual, augmented, and mixed reality technology company, a first-of-its-kind post-traumatic stress disorder (PTSD) and addiction treatment solutions program for veterans in the metaverse setting.

See the original post here:
BioCorRx Featured on LiveNOW from FOX

Global News Feed Comments Off on BioCorRx Featured on LiveNOW from FOX | June 20th, 2022

NEW YORK and MAINZ, GERMANY, June 17, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine as a three 3-µg dose series for children 6 months through 4 years of age (also referred to as 6 months to less than 5 years of age). The 3-µg dose was carefully selected as the preferred dose for children under 5 years of age based on safety, tolerability, and immunogenicity data.

More:
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

Global News Feed Comments Off on Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age | June 20th, 2022

POMPANO BEACH, FLORIDA, June 17, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies® (OTC: BSEM), a leading, innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies will be hosted on Benzinga’s All Access show, which airs on Benzinga TV and Benzinga’s YouTube channel on June 17 2022, at 10:20 AM EST.

Read more:
BioStem Technologies® CEO to Appear on the Benzinga All Access Show on June 17,2022

Global News Feed Comments Off on BioStem Technologies® CEO to Appear on the Benzinga All Access Show on June 17,2022 | June 20th, 2022

Company Announcement

See the original post here:
Genmab Announces Initiation of Share Buy-Back Program

Global News Feed Comments Off on Genmab Announces Initiation of Share Buy-Back Program | June 20th, 2022

SAN DIEGO, CA and TAICANG, SUZHOU, China, June 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”) announced on June 16, 2022, Connect Biopharma Holdings Limited (the “Company”) received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s American Depositary Shares (“ADSs”) had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5550(a)(2).

The rest is here:
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Global News Feed Comments Off on Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | June 20th, 2022

NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, today disclosed the receipt of a notice (the “Notice”) on June 14, 2022 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s common shares on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until December 12, 2022 (the “Compliance Deadline”), to regain compliance with the Minimum Bid Price Requirement by having the closing bid price of the Company’s common shares meet or exceed $1.00 for at least ten consecutive business days.

See the original post:
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice

Global News Feed Comments Off on Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice | June 20th, 2022

Oral presentation will outline design of first ever Phase 1/2 clinical trial of regenerative human cell therapy in epilepsy

Read the original:
Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy,...

Global News Feed Comments Off on Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy,… | June 20th, 2022

BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Dr. Phillip Schwartz, the Company’s President of Research & Development and Founder, will resign from his current role effective July 21, 2022 to pursue other opportunities. Dr. Schwartz also stepped down from the Company’s Board of Directors, effective June 15, 2022. Dr. Schwartz’s resignation was not a result of any disagreement with the Company and Dr. Schwartz will remain as a consultant to the Company.

More:
Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities

Global News Feed Comments Off on Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities | June 20th, 2022

SHANGHAI, China, June 20, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced the appointment of Donna Ambrosino, M.D., and Ralf Clemens, M.D., Ph.D., to the company’s Board of Directors.

See original here:
Clover Appoints Donna Ambrosino, M.D., and Ralf Clemens, M.D., Ph.D., to Board of Directors

Global News Feed Comments Off on Clover Appoints Donna Ambrosino, M.D., and Ralf Clemens, M.D., Ph.D., to Board of Directors | June 20th, 2022

Saint-Herblain (France) and New York, June 20, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022.

Go here to read the rest:
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

Global News Feed Comments Off on Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15 | June 20th, 2022

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has submitted a regulatory filing to the Brazil National Health Surveillance Agency (ANVISA) for UPLIZNA for the treatment of adult patients with anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD).

This regulatory submission is an important milestone as we continue to expand our commitment to NMOSD patients around the world, said Vikram Karnani, executive vice president and president, international operations, Horizon. NMOSD is a devastating disease with unpredictable attacks, which can result in potential loss of vision and motor function. We are hopeful that we can bring a potential new treatment option to the estimated ten thousand people living with NMOSD in Brazil.

In the N-MOmentum Phase 3 clinical trial, the largest NMOSD trial to date, UPLIZNA demonstrated a significant reduction in the risk of an NMOSD attack with only two infusions per year, following the initial two loading doses. Additionally, 89% of patients in the AQP4-IgG+ group remained attack-free during the six-month period post-treatment and 83% of patients on treatment remained attack-free for at least four years.1,2

UPLIZNA was approved by the U.S. Food and Drug Administration (FDA) in June 2020, by the Japanese Ministry of Health, Labor and Welfare in March 2021 and by the European Commission (EC) in April 2022. Mitsubishi Tanabe Pharma Corporation has the rights to develop and commercialize UPLIZNA in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore and Taiwan. Hansoh Pharmaceutical Group Company Limited, another strategic partner to Horizon, has also recently received manufacturing and marketing approval from the National Medical Products Administration of the Peoples Republic of China for UPLIZNA.

About Neuromyelitis Optica Spectrum Disorder (NMOSD)

NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes. NMOSD is a rare, severe, relapsing, neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord, brain and brain stem.3-4 Approximately 80% of all patients with NMOSD test positive for anti-AQP4 antibodies.5 AQP4-IgG binds primarily to astrocytes in the central nervous system and triggers an escalating immune response that results in lesion formation and astrocyte death.6

Anti-AQP4 autoantibodies are produced by plasmablasts and plasma cells. These B-cell populations are central to NMOSD disease pathogenesis, and a large proportion of these cells express CD19.7 Depletion of these CD19 B cells is thought to remove an important contributor to inflammation, lesion formation and astrocyte damage. Clinically, this damage presents as an NMOSD attack, which can involve the optic nerve, spinal cord and brain.6-8 Loss of vision, paralysis, loss of sensation, bladder and bowel dysfunction, nerve pain and respiratory failure can all be manifestations of the disease.9 Each NMOSD attack can lead to further cumulative damage and disability.10,11 NMOSD occurs more commonly in women and may be more common in individuals of African and Asian descent.12,13

About UPLIZNA (inebilizumab-cdon)

INDICATION

UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

IMPORTANT SAFETY INFORMATION

UPLIZNA is contraindicated in patients with:

WARNINGS AND PRECAUTIONS

Infusion Reactions: UPLIZNA can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash or other symptoms. Infusion reactions were most common with the first infusion but were also observed during subsequent infusions. Administer pre-medication with a corticosteroid, an antihistamine and an anti-pyretic.

Infections: The most common infections reported by UPLIZNA-treated patients in the randomized and open-label periods included urinary tract infection (20%), nasopharyngitis (13%), upper respiratory tract infection (8%) and influenza (7%). Delay UPLIZNA administration in patients with an active infection until the infection is resolved.

Increased immunosuppressive effects are possible if combining UPLIZNA with another immunosuppressive therapy.

The risk of Hepatitis B Virus (HBV) reactivation has been observed with other B-cell-depleting antibodies. Perform HBV screening in all patients before initiation of treatment with UPLIZNA. Do not administer to patients with active hepatitis.

Although no confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) were identified in UPLIZNA clinical trials, JC virus infection resulting in PML has been observed in patients treated with other B-cell-depleting antibodies and other therapies that affect immune competence. At the first sign or symptom suggestive of PML, withhold UPLIZNA and perform an appropriate diagnostic evaluation.

Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating UPLIZNA.

Vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation, until B-cell repletion.

Reduction in Immunoglobulins: There may be a progressive and prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued UPLIZNA treatment. Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with UPLIZNA until B-cell repletion especially in patients with opportunistic or recurrent infections.

Fetal Risk: May cause fetal harm based on animal data. Advise females of reproductive potential of the potential risk to a fetus and to use an effective method of contraception during treatment and for 6 months after stopping UPLIZNA.

Adverse Reactions: The most common adverse reactions (at least 10% of patients treated with UPLIZNA and greater than placebo) were urinary tract infection and arthralgia.

For additional information on UPLIZNA, please see the Full Prescribing Information at http://www.UPLIZNA.com.

About Horizon

Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit http://www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to potential regulatory approval of UPLIZNA in Brazil and the potential benefits of UPLIZNA to patients in Brazil. These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include the risk that UPLIZNA does not receive regulatory approval in Brazil, whether, if regulatory approval is received, UPLIZNA will be successfully commercialized in Brazil, and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizons filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

References

Read more:
Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA (inebilizumab) in Brazil - Business Wire

Spinal Cord Stem Cells Comments Off on Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA (inebilizumab) in Brazil – Business Wire | June 20th, 2022

Abstract: Background Avascular necrosis of the femoral head (ANFH) is a common orthopaedic disease due to bone defects. However, few clear methods to treat ANFH in clinical practice are known. Many findings suggest that promoting the osteogenic differentiation and directional migration of stem cells may be a key method for bone regeneration. Over time, an increasing number of researchers have begun to focus on Chinese medicine and Chinese medicinal extracts; Epimedium is the Chinese herbal medicine studied in the most detail in the field of bone regeneration, and Icariin (ICA) is one of the main active ingredients in Epimedium. Objective This study aimed to explore the effects of ICA on the osteogenic differentiation and migration of bone marrow mesenchymal stem cells (BMSCs) and reveal its mechanism to provide a theoretical basis for the treatment of ANFH. Methods After primary BMSCs were freshly isolated from a normal rabbit and treated with various concentrations of ICA, the activity and proliferation of BMSCs were detected by CCK-8 assay, and the mineralized nodules was detected by Alizarin Red staining, to determine the optimal concentration of ICA. qPCR and western blot were used to demostrate the effects of ICA on the osteogenic differentiation and migration of BMSCs. Osteoblasts-derived exosomes (OB-exos) were extracted and analysed by high-throughput sequencing. Effect of ICA combined with OB-exos were analysed. And miRNA mimic and an miRNA inhibitor were synthetised to verify the osteogenic differentiation and migration of BMSCs alone or co-cultured with ICA. Results The CCK-8 assay and Alizarin Red staining showed that the optimal concentration of ICA is 1107 M. ICA could effectively promote the osteogenic differentiation and migration of BMSCs, and this could be enhanced after co-culturing with OB-exos. The four miRNAs with the greatest concentrations in the OB-exos were let-7a-5p, miR-100-5p, miR-21-5p and miR-122-5p. qPCR and western blot showed that miR-122-5p mimic has positive effects on the osteogensis and migration, and its inhitiotr has negative effects. Simliarly, they could enhance or inhitor the effects of ICA, which means miR-122-5p may be the target of ICA. Conclusion Like the OB-exos, ICA could obviously promote the osteogenic differentiation and migration of BMSCs. The combination of ICA and OB-exos enhanced these effects, in which miR-122-5p plays a pivotal role.

Continued here:
Mechanism of Icariin regulation of the effect of miR-122-5p in osteoblast-derived exosomes on osteogenesis and migration of bone marrow mesenchymal...

Bone Marrow Stem Cells Comments Off on Mechanism of Icariin regulation of the effect of miR-122-5p in osteoblast-derived exosomes on osteogenesis and migration of bone marrow mesenchymal… | June 11th, 2022

Myeloproliferative neoplasms (MPNs) are a diverse group of chronic hematological diseases caused by the clonal expansion of abnormal hematopoietic stem cells, of which polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) have been extensively studied in terms of clonal expansion, fibrosis, and other phenotypes. For a study, researchers sought to evaluate current research on the impact of different types of MPN on bone health.

Human data were used in research to show that different types of MPN influence bone density, osteoblast proliferation, and differentiation. The majority of data revealed that bone volume is frequently raised in patients with PMF. In contrast, it was slightly decreased or not affected in patients with ET or PV; however, probable distinctions between male and female phenotypes in most MPN subtypes have not been thoroughly examined.

Osteosclerosis in PMF patients was a significant consequence that could result in bone marrow failure, and bone loss seen in some ET or PV patients can result in osteoporotic fractures. Some MPN types were associated with an increase in the number of megakaryocytes (MKs), and various MK-related MPN variables are known to impact bone formation.Investigators discussed known mechanisms involved in the processes, emphasizing the function of MKs and secreted factors. Understanding MPN-related alterations in bone health should lead to better early intervention and treatment of this pathologys adverse effects.

Reference:ashpublications.org/blood/article-abstract/139/21/3127/476662/Myeloproliferative-disorders-and-their-effects-on?redirectedFrom=fulltext

See the original post:
Myeloproliferative Disorders & Bone Homeostasis: The Role of Megakaryocytes - Physician's Weekly

Bone Marrow Stem Cells Comments Off on Myeloproliferative Disorders & Bone Homeostasis: The Role of Megakaryocytes – Physician’s Weekly | June 11th, 2022

A new study has identified a possible target for treating juvenile myelomonocytic leukemia, a highly aggressive blood cancer.

Research into a type of blood cancer called juvenile myelomonocytic leukemia suggests anti-inflammatory treatment as a possible new therapy for the disease

Juvenile myelomonocytic leukemia (JMML) is most common in children under the age of four. 10% of all cases occur in newborns under the age of three months. Every year, one to two children out of a million are diagnosed with JMML. The disease accounts for approximately 1.6 percent of all blood-related cancers. It is more common in males, with boys being nearly twice as likely as girls to develop JMML.

The exact underlying causes of JMML are unclear, however, virtually all patients will have a mutation in a RAS gene or a gene that affects the activation levels of Ras proteins that modifies the DNA within their blood cells. Currently, allogeneic hematopoietic stem cell transplantation is the only successful treatment for the majority of patients, although recent advancements show promise.

According to a report published on May 10th, 2022, in the journal eLife, scientists have identified a potential new target for treating patients with the blood cancer juvenile myelomonocytic leukemia (JMML).

Their findings in zebrafish and JMML patients suggest that anti-inflammatories may be a new approach to fighting the disease.

JMML is a highly aggressive blood cancer with poor patient outcomes. Children with Noonan Disease (NS), a relatively common developmental syndrome, are at a high risk of having a disorder similar to JMML called myeloproliferative neoplasm, which may later progress to JMML. A mutation in the PTPN11 gene, which encodes the protein-tyrosine phosphatase SHP2, is the most common genetic cause of JMML and NS.

Hematopoietic stem and progenitor cells are considered to be the cells of origin for JMML, says first author Maja Solman, Postdoctoral Fellow at the Hubrecht Institute, Utrecht, Netherlands. Currently, hematopoietic stem cell transplantation is the only treatment for the disease, but it has a relapse rate of 50%. With such limited treatment options for JMML, we wanted to gain a better understanding of how the disease develops to identify other possible ways of targeting it.

This image shows the macrophages (red) and neutrophils (green) in a zebrafish embryo with a mutation in SHP2. The head of the embryo is on the left, the tail on the right. Similar to the situation in JMML patients, this fish has more macrophages and neutrophils compared to fish without a mutation in SHP2. Credit: Maja Solman

To do this, Solman and the team used a novel zebrafish model with a mutation in SHP2 equivalent to the most common mutation in NS patients which can cause JMML. They used a technique called single-cell transcriptomics to examine the level of gene expression in the animals hematopoietic stem and progenitor cells. The analysis showed an increase in the number of monocyte and macrophage progenitor cells in the fish embryos, and that these cells expressed genes associated with the immune response.

The team next compared these results with their analysis of hematopoietic stem and progenitor cells, which contained SHP2 mutations, from the bone marrow of JMML patients. They found a similar pattern of proinflammatory gene expression in these cells to the one they identified in the zebrafish.

Finally, they treated the zebrafish embryos with an anti-inflammatory drug called dexamethasone. They found that the drug helped rescue JMML-like blood defects in the fish, suggesting that anti-inflammatories could one day be an important treatment strategy for JMML.

Our work reveals striking similarities in the proinflammatory response of human and zebrafish cells containing SHP2 mutations, and shows that inhibiting this response can improve JMML-like symptoms in a zebrafish model, concludes senior author Jeroen den Hertog, Group Leader and Managing Director at the Hubrecht Institute, and Professor of Molecular Developmental Zoology at Leiden University, Netherlands. Together, these findings lay the groundwork for future studies to verify the effectiveness of anti-inflammatories as a potential new treatment approach for JMML patients.

Reference: Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects by Maja Solman, Sasja Blokzijl-Franke, Florian Piques, Chuan Yan, Qiqi Yang, Marion Strullu, Sarah M Kamel, Pakize Ak, Jeroen Bakkers, David M Langenau, Hlne Cav and Jeroen den Hertog, 10 May 2022, eLife.DOI: 10.7554/eLife.73040

Read more:
New Treatment for Highly Aggressive Blood Cancer - SciTechDaily

Bone Marrow Stem Cells Comments Off on New Treatment for Highly Aggressive Blood Cancer – SciTechDaily | June 11th, 2022

Pervez Musharraf served as Pakistan's president from 2001 to 2008.

The family of former Pakistan President Pervez Musharraf (retired) has said that he has been hospitalised for the last three weeks after his condition worsened. In a statement posted on Twitter on Mr Musharraf's official Twitter account, his family said that he is dealing with Amyloidosis and prayed for ease in his daily living.

"He is not on the ventilator. Has been hospitalized for the last 3 weeks due to a complication of his ailment (Amyloidosis). Going through a difficult stage where recovery is not possible and organs are malfunctioning. Pray for ease in his daily living," the tweet said.

According to National Health Service (NHS) of the UK, Amyloidosis is the name for a group of rare, serious conditions caused by a build-up of an abnormal protein called amyloid in organs and tissues throughout the body.

Amyloid deposits can build up in the heart, brain, kidneys, spleen and other parts of the body.

The build-up of these protein deposits can make it difficult for the organs and tissues to work properly. Without treatment, this can lead to organ failure, the NHS further said.

Mr Musharraf was diagnosed with the life-threatening health condition in 2018 in the UAE.

Amyloidosis may be secondary to a different health condition or can develop as a primary condition, according to Johns Hopkins Medicine. Sometimes it is due to a mutation in a gene, but other times the cause of amyloidosis remains unknown, it added.

There are different types of the Amyloidosis, which are prevalent:

Light-chain (AL) Amyloidosis: It can affect the kidneys, spleen, heart, and other organs. People with conditions such as multiple myeloma or a bone marrow illness called Wadenstrom's macroglobulinemia are more likely to have AL amyloidosis.

AA Amyloidosis: It is caused by fragments of amyloid A protein, and affects the kidneys in about 80 per cent of cases. It can complicate chronic diseases characterized by inflammation, such as rheumatoid arthritis (RA) or inflammatory bowel disease (IBS).

Transthyretin Amyloidosis (ATTR): It can be inherited from a family member. Transthyretin is a protein that is also known as prealbumin. It is made in the liver. Excessive normal (wild-type ATTR) or mutant transthyretin can cause amyloid deposits.

Though there are some common symptoms of the disease, they vary greatly depending on where the amyloid protein is collecting in the body.

The general symptoms include (listed by Johns Hopkins on its website):

As Amyloidosis progresses, the deposits of amyloid can harm the heart, liver, spleen, kidneys, digestive tract, brain or nerves.

The diagnosis of Amyloidosis is hard, as the symptoms are generic. The doctors take a small sample of the tissue (biopsy) from the affected part to understand what kind of Amyloidosis is present. Depending on that, the treatment is done.

There is not currently a cure for amyloidosis. The amyloid deposits cannot be directly removed. So the doctors may discuss:

Chemotherapy, which is used to kill cancer cells or stop them from growing and similar method can be adopted to stop the growth of cells that are making abnormal protein.

Bone marrow transplant: In this procedure, healthy stem cells are taken from a patient's body. They are then infused back into their body to replace the unhealthy ones destroyed in chemotherapy.

There are some medicines too, which are used to treat Amyloidosis. These medicines are approved by the Food and Drug Administration (FDA) in the United States.

Waiting for response to load...

Read the original post:
What Is Amyloidosis, The Health Condition Pervez Musharraf Is Suffering From - NDTV

Bone Marrow Stem Cells Comments Off on What Is Amyloidosis, The Health Condition Pervez Musharraf Is Suffering From – NDTV | June 11th, 2022

The new report by Expert Market Research titled, Global Live Cell Imaging Market Report and Forecast 2022-2027, gives an in-depth analysis of the global live cell imaging market, assessing the market based on its segments like product type, application, technology, and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.

Request a free sample copy in PDF or view the report [emailprotected] https://bit.ly/3mtMGEU

The key highlights of the report include:

Market Overview (2017-2027)

As the number of stem cell research projects grows, so does the use of live cell imaging tools to analyse the location, purity, and amount of cells and their components, boosting market growth. The use of live cell imaging tools to precisely detect protein levels for optimal medication therapy is rising, as it is critical to determine the interaction between stem cells and tissues during stem cell research. The introduction of numerous government initiatives to support research and development (R&D) activities is fueling the live cell imaging industrys expansion. For example, in March 2020, the Canadian government announced a $6.9 million investment to promote stem cell research efforts in the country through the Stem Cell Networks research financing programme.

Furthermore, the increasing use of live cell imaging in the discovery of new medications is propelling the market forward. The development of new technologies that allow for the precise analysis of RNA, nucleic acid, proteins, and DNA, among other things, is driving demand for many diagnostic methods, moving the market forward. Furthermore, the rise in the prevalence of chronic diseases like cancer is driving up demand for live cell imaging in both diagnosis and treatment. The expanding research and development (R&D) activities to detect cancer cells in bone marrow while also allowing for the identification of specific cancer cells are likely to boost market growth.

Industry Definition and Major Segments

The study of living cells using microscope technology to obtain images of live cells and tissues is known as live cell imaging. It is essential in a variety of laboratory operations in biological and biomedical research because it gives real-time and reliable information on cells and tissues, making it suitable for stem cell research and regenerative medicine development.

Explore the full report with the table of [emailprotected] https://bit.ly/3tpEoSd

By technology, the market can be divided into:

The market can be categorised based on its applications into:

The major product types of live cell imaging are:

The regional markets include:

Market Trends

Artificial intelligence (AI), deep learning, and 3D printing are progressively being integrated into live cell imaging techniques, as technology improvements are a key antecedent of scientific research and development efforts. The expanding use of artificial intelligence (AI) allows for more precise, simpler, and time-efficient cell imaging. Furthermore, AI-based microscopy can recognise and analyse minor cell components like nuclei, allowing researchers to analyse data more quickly and effectively. AI-based microscopes also automate and optimise many functions for quantifying live cells, resulting in increased cell viability and faster image capture. This is fueling the expansion of the live cell imaging sector by increasing demand for such microscopes in research centres.

Furthermore, the increasing use of 3D printing in a variety of medical and biological applications is fueling market expansion. Because air bubbles are a common problem in perfusion chambers used in live cell imaging, the demand for fluidic devices made with 3D printing technology is increasing dramatically. Furthermore, the cost-effectiveness of 3D printing is increasing the affordability of live cell imaging research operations, which is propelling the market forward. In the forecast future, the development of portable and low-profile devices that can be directly installed on optical microscopes to improve cell imaging precision is expected to drive market expansion for live cell imaging.

Latest News on Global Live Cell Imaging [emailprotected] https://bit.ly/3HaaQ0z

Key Market Players

The major players in the market are Carl Zeiss AG, Leica Microsystems GmbH, Nikon Instruments Inc., Becton, Dickinson and Company, GE Healthcare and Others.

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.

At Expert Market Research, we tailor our approach according to our clients needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.

Media Contact

Company Name: Claight CorporationContact Person: Sofia Williams, Corporate Sales Specialist U.S.A.Email: [emailprotected]Toll Free Number: +1-415-325-5166 | +44-702-402-5790Address: 30 North Gould Street, Sheridan, WY 82801, USACity: SheridanState: WyomingCountry: United StatesWebsite: https://www.expertmarketresearch.com

Read More Reports:-

Global Laser Hair Removal Market: https://spooool.ie/2022/04/06/global-laser-hair-removal-market-to-be-driven-by-rising-disposable-income-in-india-and-china-in-the-forecast-period-of-2021-2026/

Global Riflescopes Market: https://spooool.ie/2022/04/06/global-riflescopes-market-to-be-driven-by-the-rising-demand-for-precision-attack-technologies-in-the-forecast-period-of-2021-2026/

Introducing Procurement Intelligence Servicesof EMR Inc.

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Follow this link:
Global Live Cell Imaging Market to be Driven by Growing Stem Cell Research Market in the Forecast Period of 2022-2027 mbu timeline - mbu timeline

Bone Marrow Stem Cells Comments Off on Global Live Cell Imaging Market to be Driven by Growing Stem Cell Research Market in the Forecast Period of 2022-2027 mbu timeline – mbu timeline | June 11th, 2022

The BioIntelliSense BioSticker. Photo courtesy of BioIntelliSense.

James Byrne hadnt been out of the hospital for long when a call came in after midnight. He answered to the voice of a triage nurse asking him how he was feeling. He was pretty tired, actually, having been through radiation treatment and chemotherapy designed to eradicate his acute myeloid leukemia and then an allogeneic bone marrow transplant (his son Logan had been the key donor; his cells were augmented with donated umbilical-cord stem cells). That and having been asleep until his cell phone rang. But otherwise, just fine, he said.

Good to hear, the nurse said because Byrnes body temperature had just jumped to 98.9 degrees. While thats just a shade higher than the standard 98.6 degrees, his temperature had been hanging around 97 degrees, so what would otherwise seem normal might instead have been an indication of a brewing infection. Given that his immune system had been wiped out and was just starting to rebuild itself, an infection would pose a serious risk to the 45-year-old resident of Albuquerque, N.M. This was, fortunately, a red flag that could be safely lowered again.

Byrne would have had a hard time taking his own temperature while sound asleep. A three-inch by one-inch, U.S. Food and Drug Administration-approved medical device called a BioSticker had done that and much more.

Before Byrne left UCHealth University of Colorado Hospital on the Anschutz Medical Campus, the UCHealth and University of Colorado School of Medicine advanced practice practitioner leading the study, Glen Peterson, had asked him if he might be interested in joining one of two cancer-related clinical trials using the remote-monitoring gadget developed by Golden-based BioIntelliSense. This one would involve sticking the BioSticker to his upper chest and largely forgetting about it for 30 days. The BioSticker would collect a steady stream of his vital signs body temperature, respiratory rate, resting heart rate, skin temperature, gait, body position and more and transmit it to UCHealth providers via a wireless hub and Reimagine Care, a startup focused on home cancer care. The goal would be to spot emerging health problems before Byrne himself did.

Its not the first work UCHealth has done with BioIntelliSense. Their collaborations through the UCHealth CARE Innovation Center have most notably involved remote monitoring of high-risk COVID-19 patients. But Dr. Richard Zane, UCHealths chief innovation officer and chair of the CU School of Medicines Department of Emergency Medicine, says the technology could apply to a wide range of health conditions.

Its about bringing remote patient monitoring to wherever the patient is, understanding how to ingest key vital signs, and building predictive and prescriptive algorithms on top of those data so that we can intervene before we otherwise would have, Zane said.

Technologies such as BioIntelliSenses BioSticker and the recently announced BioButton an even-smaller stick-on medical device that captures much of the same data as its predecessor have the potential to supplant an outdated system of discharged patients self-reporting their own health status, as Dr. Clay Smith, director of the UCHealth Blood Disorders and Cell Therapies Center and associate chief of the CU School of medicines Division of Hematology, put it.

Byrnes example of having a lower-than-usual body temperature is a case in point. The typical approach of having people take their temperature a couple of times a day and report fevers to caregivers assumes 98.6 as the normal temperature. But it can vary from person to person, as it did with Byrne; it can be lowered by medications; it can go up on a hot day or even when wearing a hat. A long-term monitoring device such as the BioSticker, which captures and transmits 1,440 measurements every 24 hours, day and night, can establish baselines from which to judge abnormalities.

We see people who are quite ill who have a normal temperature and those with a higher temperature who are fine, Smith said.

The second UCHealth-BioIntelliSense study also relates to body temperature. That study, which Peterson also leads, involves cancer patients whose chemotherapy has left them with low numbers of white blood cells called neutrophils that help fight infections. These patients are susceptible to febrile neutropenia a fever caused by an infection that exploits the weakened immune system. Febrile neutropenia cases account for about 5% of all adult cancer-related hospitalizations in the United States, with an average stay of more than eight days.

The sooner one can spot a fever or other signs of nascent illness, the faster the patient can get treatment.

We know that, the longer you wait from the time infection starts, the worse the outcomes, Smith said. Its important to detect it as soon as possible, figure out what type of infection it is, and start antibiotics.

Fevers are only the beginning, Smith says. He sees technologies such as the BioSticker feeding diverse readings into artificial-intelligence-powered systems capable of synthesizing body temperature, heart rate, respiratory rate, movement characteristics, and other factors to detect a whole range of problems and alert health care providers to nip health problems in the bud.

Zane says BioIntelliSenses work with UCHealth is already moving in that direction. Theyve identified patterns in the data that seem to predict fevers while a patients temperature is still normal. Such insight could one day let providers prescribe antibiotic pills for patients at home to beat back infections before theyre serious, thereby avoiding hospitalization for intravenous antibiotics.

James Byrnes BioSticker has triggered a few calls over the month he has worn it, he says. One involved a 3:30 a.m. call from a nurse practitioner triggered by a change in his breathing patterns and indeed, he had been coughing for much of the night. The nurse had him check his pulse oxygen level; it was normal.

Another had to do with a leap in his heart rate. He happened to have been walking around quite a bit at the time, he says, and he isnt in the best shape of his life for obvious reasons. The triage nurse explained why she was calling and asked, You doing alright?

Im doing just fine, he answered.

But it was nice to get that call.

Read the original here:
BioSticker detects more than just fever in cancer patients - UCHealth Today

Bone Marrow Stem Cells Comments Off on BioSticker detects more than just fever in cancer patients – UCHealth Today | June 11th, 2022

InThe Moment, a new podcast series from The Athletic,Kelly Cates and Geoff Thomas speak to sportspeople about experiencing and overcoming times of adversity that changed their lives forever.

In this weeks episode, former England footballer Thomas discusses his own recovery from leukaemia and his determination to raise millions of pounds for blood cancer research by completing the route of cyclings arduous Tour de France, just 18 months after undergoing a stem cell transplant.

When Geoff Thomas was told he had three years to live, it seemed like a lifetime.

Just 24 hours earlier, hed believed it was no more than three months.

It was July 2003 and the former Crystal Palace, Wolves and England footballer had been diagnosed with chronic myeloid leukaemia. Id only been retired from football about six to eight months, he says. Id started suffering from fatigue and I was having night sweats and various things but, a typical man, was putting off going to see a doctor.

On the morning of July 4, Thomas finally went to see his doctor. Blood was taken for testing and he was sent home with the message that the results would come back in three weeks time.

About three or four hours later, I got the phone call that changed my life. It was a call that told me I had a form of leukaemia. I was told I could be in the blast phase which, when I stupidly went on the internet, meant it looked like I could only have three months to live.

The following day, Thomas was introduced to bone-marrow specialist Professor Charlie Craddock, who attached him to a machine which helped confirm that, in fact, he had three years to live. The only slim chance of him surviving his leukaemia was to find a stem cell match for a transplant.

Back in 2003, chronic myeloid leukaemia was more or less a death sentence if you couldnt find a match to have a stem cell transplant. And thats only 20 per cent of the population that can do that.

When youre told the brutal honesty about whats ahead of you, you know, the chances of you not surviving is really pretty high. So youre looking for any positives to put you on that positive track.

I read a book about Lance Armstrongs journey the second day I was diagnosed, and I know his name has been tarnished since (Armstrong was stripped of his seven Tour de France and banned from pro cycling for life for doping offences), but his fightback and his desperation to find the best way of surviving his cancer put me on that track. I wanted to turn every stone to give myself the opportunity of surviving this.

Its almost 19 years now since that diagnosis but, mentally and emotionally, Thomas can put himself back on that ward in an instant. I can know exactly what the conversations were and exactly how myself and my wife were handling it: not very good for the first three days, but we had to protect our 10- and seven-year-old little girls, and make sure they were OK.

For the next couple of weeks from being diagnosed, I was looking at what their future looked like without me, to be honest. I was looking to see if they were insured properly, if the house was safe if I disappeared. That was extra comfort, but Ive realised that so many other people dont have that opportunity.

Four days after he was diagnosed, Thomas sister Kay went for blood tests to see if she was a stem cell match. It would take over a month for the results to come back and they were told there was just a one-in-five chance she would be suitable. In the meantime, Thomas and wife Julie made a list of trips they wanted to go on with their two girls. We went off to places like Disneyland Paris and just tried to shield them as much as we could by enjoying ourselves.

Bizarrely, I was in a really good space in my mind because for the first time I realised what was really important in life. And it wasnt the fast cars, it wasnt the bigger house, it wasnt getting a bigger garden. It was just purely your health and your family and being able to be around them.

Thats something I try to keep. When Im starting to have little down days, I try and keep that message within that things could be a hell of a lot worse.

Thomas was fortunate that Kay was a match. Not a very good match, he qualifies. So the doctors had to do some tweaking. But it was good enough for me to go into isolation for five to six weeks and really be beaten up with chemotherapy and radiotherapy. They more or less take everything down to ground level and build you back up again. You purely put your life in the hands of the great guys and nurses at the hospital.

He was put on an intensive course of chemotherapy and radiotherapy to prepare his body for the transplant. At that point, he says your immune system is gone. A simple cold could kill you. Then, all of a sudden, they bring this bag in. Its only about eight inches long, and its just full of a browny, horrible colour.

They hang it up on the little pole and you see it going down the tube and going through your body that was my sisters stem cells. It took a good eight hours to be put in.

The next day, I was really, really poorly. The nurses warned Julie, It doesnt look good. Hes been struggling. And it was probably the lowest point of everything I went through. I didnt think I was going to make it. But Julie just put her arm around me and gave me a hug for about a couple of hours.

After a few days, there were indications that his immune system was starting to work. It was a positive sign. But it would take around six months for Thomas to feel normal again.

It was January 2004 when Thomas had the transplant, and a year later when he received the momentous news that he was in remission, albeit with the knowledge that the treatment hed received could put him at risk of developing different cancers later in life.

The attitude and mentality he developed during a 20-year long football career has played a key role in helping Thomas through the difficult times he suffered. In football, youve got to have good coaches. Youve got to have good trainers to make you the sportsperson you become, he says. But most importantly, you need to have your own determination to make that happen and to be willing to keep learning and keep improving on everything.

Theres so many parallels; the manager turned into the professor. Your team-mates turned into fellow patients. And the nurses were coaches.

And so my mindset was not to try and say, Im going to beat this. I was being honest with everybody. I said, I dont know if Im going to. Like in football, I dont know if were going to win on Saturday, but well try our damnedest to make sure that we do everything to get a good result.

In sport, you find that any negative thought is detrimental to your performance on the Saturday. And I think any negative thought when youre battling an illness is detrimental to your battle as well.

Ive even seen people who have had a positive outcome not able to move away from the illness itself, so they live with that journey theyve been on. And rather than taking it into a positive, theyve kept it like a shroud of darkness around them. Its tough watching these sorts of people.

Thomas still has days when the enormity of what he faced gives him the shivers. It hits me when I see other people going through it, he says. Selfishly, I dont sometimes respond to their story its like it brings my story back. There probably were times where I should have been a lot more open about my feelings but I wasnt. I just buried it.

Ive met a number of footballers who have been touched with blood cancer since. Stiliyan Petrov I met when he was just diagnosed and I just said, Listen, open yourself up to everybody and let your emotions out, because I didnt cry for a while and I felt so much better when I did.

From almost the minute he was diagnosed, Thomas was looking for ways to utilise the profile he had from football to help those who were helping him. On the second day after he met Professor Craddock, he asked him what he could do. I always remember his answer, Thomas says. Let me get you better first, then Ill come back to you. And thats what hes been doing ever since.

A sponsored run or walk is the first port of call for most people who want to find a way to say thank you to the doctors and nurses who have helped them. But as a former professional footballer, Thomas felt he needed to do something more.

Hed already seen former England cricketer Sir Ian Botham walk hundreds of miles to raise funds for leukaemia research and the competitive streak in him told him he needed to surpass that.

A good friend of mine now, Neil Ashton, was following my story he was a reporter back then. He said, Why dont you do the Tour (de France)?. I didnt know what the Tour was, really. I watched it now and then without knowing what was really going on.

Thomas said hed think about it and get back to him. That was February 2005. Id gone into remission in January 2005. And by July, I was doing exactly the same mileage as a professional cyclist just a hell of a lot slower. I found myself doing nearly two and a half thousand miles on a bike and riding some horrendous climbs in the Alps and the Pyrenees.

That was the moment I got my life back. There were stages in there that were so tough that it definitely brought tears to my eyes. But the strength I took on was of the people Id met over the previous two years who hadnt made it; all these stories Ive got deep in the back of my mind.

They always come to the fore when Im going through a little struggle myself, because these people would love to be in my situation when I was going up these climbs. Theyre the people I still call on now and then to keep me going.

Was it medically advisable to put his body through such an intense experience: 21 stages and 2,233 miles? Thomas smiles. Charlie said that in a similar sort of timeline, people normally come and ask him, Is it OK to start swimming?.

He raised over 150,000 that year from cycling the Tour route, and two years later set up the Geoff Thomas Foundation to fund clinical research into leukaemia. In the years since, he has raised hundreds of millions of pounds, helping to fund clinical trial networks, get more drugs into the treatment system and build an infrastructure that allows work to flow and benefits patients.

We need an awful lot more to enable us to fulfill the vision of the blood cancer professors up and down this country because they believe we can beat this in 10 to 15 years eradicate blood cancer. Its such a strong message to get out there and people can see the improvement over the last 15 years that we are getting there.

Collectively, we can beat this.

Listen and subscribe to The Athletics The Moment podcast, including the first episode with Gary Lineker.

(Lead graphic: Sam Richardson)

Link:
The Moment: Geoff Thomas After being diagnosed with leukaemia, I was looking at what my girls future looked like without me - The Athletic

Bone Marrow Stem Cells Comments Off on The Moment: Geoff Thomas After being diagnosed with leukaemia, I was looking at what my girls future looked like without me – The Athletic | June 11th, 2022